Status and perspectives of neuroprotective therapies in glaucoma: The European Glaucoma Society White Paper

Cell and Tissue Research

Volumn 353, Issue 2, 2013, Pages 347-354

  Tamm, Ernst R ^a   Schmetterer, Leopold ^b   Grehn, Franz ^c  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Glaucoma; Neuroprotection; Retina; Retinal ganglion cells; Therapy

Indexed keywords

BRIMONIDINE; CILIARY NEUROTROPHIC FACTOR; MEMANTINE; PLACEBO;

ADAPTIVE OPTICS; APOPTOSIS; CONFOCAL LASER MICROSCOPY; DETECTION OF APOPTOSING RETINAL CELL; DRUG DOSE COMPARISON; ELECTRORETINOGRAM; EVOKED VISUAL RESPONSE; GLAUCOMA; GLIA CELL; HUMAN; INTRAOCULAR PRESSURE; LOW DRUG DOSE; NERVE REGENERATION; NEUROPROTECTION; NEURORETINAL RIM; NONHUMAN; OPTIC NERVE; OPTICAL COHERENCE TOMOGRAPHY; OPTICS; PRIORITY JOURNAL; RETINA DEGENERATION; RETINA GANGLION CELL; RETINA MACULA AGE RELATED DEGENERATION; RETINAL NERVE FIBER LAYER THICKNESS; REVIEW; SCANNING LASER POLARIMETRY; STEM CELL TRANSPLANTATION; VISUAL FIELD DEFECT; VISUAL SYSTEM PARAMETERS;

APOPTOSIS; BIOLOGICAL MARKERS; CONGRESSES AS TOPIC; DISEASE PROGRESSION; EUROPE; GLAUCOMA; HUMANS; NEUROPROTECTIVE AGENTS; OPTICS AND PHOTONICS; RESEARCH REPORT; RETINAL GANGLION CELLS; SOCIETIES, MEDICAL; STEM CELL TRANSPLANTATION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84880765892     PISSN: 0302766X     EISSN: 14320878     Source Type: Journal    
DOI: 10.1007/s00441-013-1637-3     Document Type: Review

References (80)

1. Alencar LM, Zangwill LM, Weinreb RN, Bowd C, Vizzeri G, Sample PA, Susanna R Jr, Medeiros FA (2010) Agreement for detecting glaucoma progression with the GDx guided progression analysis, automated perimetry, and optic disc photography. Ophthalmology 117:462-470
2. Anderson DR, Hendrickson A (1974) Effect of intraocular pressure on rapid axoplasmic transport in monkey optic nerve. Invest Ophthalmol 13:771-783
3. Bach M, Poloschek C (2013) Electrophysiology and glaucoma: current status and future challenges. Cell Tissue Res (this issue)
4. Baltmr A, Duggan J, Nizari S, Salt TE, Cordeiro MF (2010) Neuroprotection in glaucoma - Is there a future role? Exp Eye Res 91:554-566
5. Berry JD, Cudkowicz ME (2011) New considerations in the design of clinical trials for amyotrophic lateral sclerosis. Clin Investig (Lond) 1:1375-1389
6. Bosco A, Steele MR, Vetter ML (2011) Early microglia activation in a mouse model of chronic glaucoma. J Comp Neurol 519:599-620
7. Buckingham BP, Inman DM, Lambert W, Oglesby E, Calkins DJ, Steele MR, Vetter ML, Marsh-Armstrong N, Horner PJ (2008) Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma. J Neurosci 28:2735-2744
8. Burgoyne CF (2011) A biomechanical paradigm for axonal insult within the optic nerve head in aging and glaucoma. Exp Eye Res 93:120-132
9. Chang EE, Goldberg JL (2012) Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement. Ophthalmology 119:979-986
10. Chauhan BC, Blanchard JW, Hamilton DC, LeBlanc RP (2000) Technique for detecting serial topographic changes in the optic disc and peripapillary retina using scanning laser tomography. Invest Ophthalmol Vis Sci 41:775-782
11. Coleman AL (2012) Advances in glaucoma treatment and management: surgery. Invest Ophthalmol Vis Sci 53:2491-2494
12. Collaborative Normal-Tension Glaucoma Study Group (1998a) Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 126:487-497
13. Collaborative Normal-Tension Glaucoma Study Group (1998b) The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 126:498-505
14. Cordeiro MF, Levin LA (2011) Clinical evidence for neuroprotection in glaucoma. Am J Ophthalmol 152:715-716
15. Cordeiro MF, Guo L, Luong V, Harding G, Wang W, Jones HE, Moss SE, Sillito AM, Fitzke FW (2004) Real-time imaging of single nerve cell apoptosis in retinal neurodegeneration. Proc Natl Acad Sci USA 101:13352-13356
16. Cordeiro MF, Nickells R, Drexler W, Borras T, Ritch R (2009) High-resolution ocular imaging: combining advanced optics and microtechnology. Ophthalmic Surg Lasers Imaging 40:480-488
17. Cordeiro MF, Migdal C, Bloom P, Fitzke FW, Moss SE (2011) Imaging apoptosis in the eye. Eye (Lond) 25:545-553
18. Cui Q, Lu Q, So KF, Yip HK (1999) CNTF, not other trophic factors, promotes axonal regeneration of axotomized retinal ganglion cells in adult hamsters. Invest Ophthalmol Vis Sci 40:760-766
19. Danesh-Meyer HV, Levin LA (2009) Neuroprotection: extrapolating from neurologic diseases to the eye. Am J Ophthalmol 148:e182
20. Diekmann H, Fischer D (2013) Glaucoma and optic nerve repair. Cell Tissue Res (this issue)
21. Downs JC, Roberts MD, Burgoyne CF (2008) Mechanical environment of the optic nerve head in glaucoma. Optom Vis Sci 85:425-435
22. Downs JC, Roberts MD, Sigal IA (2011) Glaucomatous cupping of the lamina cribrosa: a review of the evidence for active progressive remodeling as a mechanism. Exp Eye Res 93:133-140
23. Drexler W, Fujimoto JG (2008) State-of-the-art retinal optical coherence tomography. Prog Retin Eye Res 27:45-88
24. Duncan JL, Zhang Y, Gandhi J, Nakanishi C, Othman M, Branham KE, Swaroop A, Roorda A (2007) High-resolution imaging with adaptive optics in patients with inherited retinal degeneration. Invest Ophthalmol Vis Sci 48:3283-3291
25. Emerich DF, Thanos CG (2008) NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells. Curr Opin Mol Ther 10:506-515
26. Foster PJ, Buhrmann R, Quigley HA, Johnson GJ (2002) The definition and classification of glaucoma in prevalence surveys. Br J Ophthalmol 86:238-242
27. Gladstone DJ, Black SE, Hakim AM (2002) Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33:2123-2136
28. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Kass MA (2002) The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 120:714-720
29. Götzinger E, Pircher M, Baumann B, Hirn C, Vass C, Hitzenberger CK (2008) Retinal nerve fiber layer birefringence evaluated with polarization sensitive spectral domain OCT and scanning laser polarimetry: a comparison. J Biophotonics 1:129-139
30. Hare W, WoldeMussie E, Lai R, Ton H, Ruiz G, Feldmann B, Wijono M, Chun T, Wheeler L (2001) Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey. Surv Ophthalmol 45 (Suppl 3):S284-S289
31. Hart RG, Pearce LA, Ravina BM, Yaltho TC, Marler JR (2009) Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord 24:647-654
32. Henchcliffe C, Severt WL (2011) Disease modification in Parkinson's disease. Drugs Aging 28:605-615
33. Howell GR, Libby RT, Jakobs TC, Smith RS, Phalan FC, Barter JW, Barbay JM, Marchant JK, Mahesh N, Porciatti V, Whitmore AV, Masland RH, John SW (2007) Axons of retinal ganglion cells are insulted in the optic nerve early in DBA/2J glaucoma. J Cell Biol 179:1523-1537
34. Joachim SC, Reichelt J, Berneiser S, Pfeiffer N, Grus FH (2008) Sera of glaucoma patients show autoantibodies against myelin basic protein and complex autoantibody profiles against human optic nerve antigens. Graefes Arch Clin Exp Ophthalmol 246:573-580
35. Johnson TV, Bull ND, Martin KR (2011) Neurotrophic factor delivery as a protective treatment for glaucoma. Exp Eye Res 93:196-203
36. Karl MO (2013) The potential of stem cell research for the treatment of neuronal damage in glaucoma. Cell Tissue Res (this issue)
37. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO (2002) The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120:701-713
38. Kauper K, McGovern C, Sherman S, Heatherton P, Rapoza R, Stabila P, Dean B, Lee A, Borges S, Bouchard B, Tao W (2012) Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Invest Ophthalmol Vis Sci 53:7484-7491
39. Kirsch M, Lee MY, Meyer V, Wiese A, Hofmann HD (1997) Evidence for multiple, local functions of ciliary neurotrophic factor (CNTF) in retinal development: expression of CNTF and its receptors and in vitro effects on target cells. J Neurochem 68:979-990
40. Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S (2011) A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol 151:671-681
41. Kwon YH, Fingert JH, Kuehn MH, Alward WL (2009) Primary open-angle glaucoma. N Engl J Med 360:1113-1124
42. Lebrun-Julien F, Duplan L, Pernet V, Osswald I, Sapieha P, Bourgeois P, Dickson K, Bowie D, Barker PA, Di Polo A (2009a) Excitotoxic death of retinal neurons in vivo occurs via a non-cell-autonomous mechanism. J Neurosci 29:5536-5545
43. Lebrun-Julien F, Morquette B, Douillette A, Saragovi HU, Di Polo A (2009b) Inhibition of p75(NTR) in glia potentiates TrkA-mediated survival of injured retinal ganglion cells. Mol Cell Neurosci 40:410-420
44. Leibinger M, Muller A, Andreadaki A, Hauk TG, Kirsch M, Fischer D (2009) Neuroprotective and axon growth-promoting effects following inflammatory stimulation on mature retinal ganglion cells in mice depend on ciliary neurotrophic factor and leukemia inhibitory factor. J Neurosci 29:14334-14341
45. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E (2003) Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 121:48-56
46. Liang J, Williams DR (1997) Aberrations and retinal image quality of the normal human eye. J Opt Soc Am A Opt Image Sci Vis 14:2873-2883
47. Liang J, Williams DR, Miller DT (1997) Supernormal vision and high-resolution retinal imaging through adaptive optics. J Opt Soc Am A Opt Image Sci Vis 14:2884-2892
48. Liu Y, Pang IH (2013) Challenges in the development of glaucoma neuroprotection therapy. Cell Tissue Res (this issue)
49. Nguyen JV, Soto I, Kim KY, Bushong EA, Oglesby E, Valiente-Soriano FJ, Yang Z, Davis CH, Bedont JL, Son JL, Wei JO, Buchman VL, Zack DJ, Vidal-Sanz M, Ellisman MH, Marsh-Armstrong N (2011) Myelination transition zone astrocytes are constitutively phagocytic and have synuclein dependent reactivity in glaucoma. Proc Natl Acad Sci USA 108:1176-1181
50. Normando EM, Turner LA, Cordeiro MF (2013) The potential of annexin-labelling for the diagnosis and follow-up of glaucoma. Cell Tissue Res (this issue)
51. Patterson AJ, Garway-Heath DF, Strouthidis NG, Crabb DP (2005) A new statistical approach for quantifying change in series of retinal and optic nerve head topography images. Invest Ophthalmol Vis Sci 46:1659-1667
52. Pease ME, Zack DJ, Berlinicke C, Bloom K, Cone F, Wang Y, Klein RL, Hauswirth WW, Quigley HA (2009) Effect of CNTF on retinal ganglion cell survival in experimental glaucoma. Invest Ophthalmol Vis Sci 50:2194-2200
53. Pircher M, Hitzenberger CK, Schmidt-Erfurth U (2011) Polarization sensitive optical coherence tomography in the human eye. Prog Retin Eye Res 30:431-451
54. Prasse M, Rauscher FG, Wiedemann P, Reichenbach A, Franke M (2013) Optical properties of retinal tissue and the potential of adaptive optics to visulaize retinal ganglion cells in vivo. Cell Tissue Res (this issue)
55. Quigley HA (2011) Glaucoma. Lancet 377:1367-1377
56. Quigley H, Cone FE (2013) Development of diagnostic and treatment strategies for glaucoma through understanding and modification of scleral and lamina cribrosa connective tissue. Cell Tissue Res (this issue)
57. Quigley HA, Nickells RW, Kerrigan LA, Pease ME, Thibault DJ, Zack DJ (1995) Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci 36:774-786
58. Rao HL, Zangwill LM, Weinreb RN, Sample PA, Alencar LM, Medeiros FA (2010) Comparison of different spectral domain optical coherence tomography scanning areas for glaucoma diagnosis. Ophthalmology 117:1692-1699
59. Reardon G, Kotak S, Schwartz GF (2011) Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review. Patient Prefer Adherence 5:441-463
60. Reichelt J, Joachim SC, Pfeiffer N, Grus FH (2008) Analysis of autoantibodies against human retinal antigens in sera of patients with glaucoma and ocular hypertension. Curr Eye Res 33:253-261
61. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, Mariotti SP (2004) Global data on visual impairment in the year 2002. Bull World Health Organ 82:844-851
62. Seitz R, Hackl S, Seibuchner T, Tamm ER, Ohlmann A (2010) Norrin mediates neuroprotective effects on retinal ganglion cells via activation of the Wnt/beta-catenin signaling pathway and the induction of neuroprotective growth factors in Muller cells. J Neurosci 30:5998-6010
63. Seitz R, Ohlmann A, Tamm ER (2013) The role of Müller glia and microglia in glaucoma. Cell Tissue Res (this issue)
64. Shaarawy TM, Sherwood MB, Grehn F (2008) Guidelines on design and reporting of glaucoma surgical trials. Kugler, Amsterdam
65. Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR, Bush RA (2006) Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci USA 103:3896-3901
66. Sleath B, Blalock S, Covert D, Stone JL, Skinner AC, Muir K, Robin AL (2011) The relationship between glaucoma medication adherence, eye drop technique, and visual field defect severity. Ophthalmology 118:2398-2402
67. Soto I, Pease ME, Son JL, Shi X, Quigley HA, Marsh-Armstrong N (2011) Retinal ganglion cell loss in a rat ocular hypertension model is sectorial and involves early optic nerve axon loss. Invest Ophthalmol Vis Sci 52:434-441
68. Strouthidis NG, White ET, Owen VM, Ho TA, Garway-Heath DF (2005) Improving the repeatability of Heidelberg retina tomograph and Heidelberg retina tomograph II rim area measurements. Br J Ophthalmol 89:1433-1437
69. Strouthidis NG, Demirel S, Asaoka R, Cossio-Zuniga C, Garway-Heath DF (2010) The Heidelberg retina tomograph glaucoma probability score: reproducibility and measurement of progression. Ophthalmology 117:724-729
70. Talcott KE, Ratnam K, Sundquist SM, Lucero AS, Lujan BJ, Tao W, Porco TC, Roorda A, Duncan JL (2011) Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment. Invest Ophthalmol Vis Sci 52:2219-2226
71. Tezel G, Thornton IL, Tong MG, Luo C, Yang X, Cai J, Powell DW, Soltau JB, Liebmann JM, Ritch R (2012) Immunoproteomic analysis of potential serum biomarker candidates in human glaucoma. Invest Ophthalmol Vis Sci 53:8222-8231
72. The AGIS Investigators (2000) The advanced glaucoma intervention study (AGIS). 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130:429-440
73. Unsicker K (2013) Neurotrophic molecules in the treatment of neurodegenerative disease with focus on the retina: status and perspectives. Cell Tissue Res (this issue)
74. Voss T, Ravina B (2008) Neuroprotection in Parkinson's disease: myth or reality? Curr Neurol Neurosci Rep 8:304-309
75. Weber AJ (2013) Autocrine and paracrine interactions and neuroprotection in glaucoma. Cell Tissue Res (this issue)
76. Weinreb RN, Kaufman PL (2009) The glaucoma research community and FDA look to the future: a report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci 50:1497-1505
77. Weinreb RN, Kaufman PL (2011) Glaucoma research community and FDA look to the future. II. NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: measures of structural change and visual function. Invest Ophthalmol Vis Sci 52:7842-7851
78. Werkmeister RM, Dragostinoff N, Pircher M, Gotzinger E, Hitzenberger CK, Leitgeb RA, Schmetterer L (2008) Bidirectional Doppler Fourier-domain optical coherence tomography for measurement of absolute flow velocities in human retinal vessels. Opt Lett 33:2967-2969
79. Werkmeister RM, Cherecheanu AP, Garhofer G, Schmidl D, Schmetterer L (2013) Imaging of RGC in glaucoma: pitfalls and challenges. Cell Tissue Res (this issue)
80. Zhang K, Hopkins JJ, Heier JS, Birch DG, Halperin LS, Albini TA, Brown DM, Jaffe GJ, Tao W, Williams GA (2011) Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci USA 108:6241-6245